OBJECTIVES: To evaluate prior disease-modifying drug (DMD) use among currently treated and currently untreated multiple sclerosis (MS) patients.   METHODS: A random sample of MS patients (age >18 years) from the National Health and Wellness Survey or Lightspeed Research panel completed an internet survey in November/December 2012. The survey contained questions related to demographics, disease characteristics, and current and prior DMD use.  The number and percentage of patients reporting prior DMD use by current therapy groups (self-injectable DMDs, infusion DMDs, oral DMDs, and not currently on DMD) is described. RESULTS: There were 969 patients who completed the survey. Average age was 48.8 years (SD 11.3), 82.9% were female and  737 (76.1%) were currently receiving DMD treatment [self-injectable: 576 (78.2%); infusion: 84 (11.4%); oral: 77 (10.4%)]; while 232 (23.9%) were currently untreated. Among patients currently treated with a self-injectable DMD, most patients were either on their first treatment (57.7%) or had prior use of 1 DMD (27.4%). For those currently treated with an infusion DMD, 42.9% had prior use of 1 DMD, 36.9% had prior use of 2 DMDs, and 17.9% had prior use of ≥3 DMDs. For patients currently treated with an oral DMD, 27.3% had prior use of 1 DMD, 32.5% had prior use of 2 DMDs, 32.5% had prior use of ≥3 DMDs, and 7.8% were initially treated with an oral DMD. For those not currently on a DMD, 34.9% were untreated, while 33.2%, 18.5%, and 13.4% had prior use of 1, 2, or ≥3 DMDs, respectively. CONCLUSIONS: In this sample of MS patients, 8.4% had never been treated with a DMD. Most patients initiated therapy with a self-injectable DMD, while patients currently treated with infusion and oral DMDs had prior use of 1 or more DMDs.